MEDIWOUND LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.09 USD | -4.54% |
|
-6.12% | +77.88% |
| Mar. 21 | MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 | CI |
| Mar. 21 | Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024 |
Presentation Operator MessageOperator (Operator)Good day, and welcome to Media's Second Quarte...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
18.95
USD
Average target price
28.5
USD
Spread / Average Target
+50.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +77.88% | 175M | |
| -2.35% | 89.33B | |
| +4.08% | 41.19B | |
| -14.73% | 31.87B | |
| +53.68% | 24.52B | |
| -14.48% | 15.68B | |
| -8.63% | 12.34B | |
| -40.39% | 12.23B | |
| +6.22% | 8.83B | |
| -6.43% | 8.28B |
- Stock Market
- Equities
- MDWD Stock
- News MediWound Ltd.
- Transcript : MediWound Ltd., Q2 2023 Earnings Call, Aug 16, 2023